An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs Cerebroside-sulfatase (Primary)
- Indications Metachromatic leukodystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 13 Dec 2024 Planned End Date changed from 31 Dec 2024 to 30 Sep 2025.
- 13 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 30 Sep 2025.
- 06 May 2022 Planned End Date changed from 27 Apr 2023 to 31 Dec 2024.